Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Berner

Endocrinology, Diabetes & Metabolism Jasper, GA Medical Doctor

NPI 1144201781 CMS profile 97355

220 J L White Dr, Suite 110, Jasper, GA 30143

Open in the dashboard

General payments

$457,107

1,850 records reported · program years 2019–2025

Research payments

$27,787

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,155,605 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Jason Berner of Jasper, GA is reported in the CMS Open Payments database as having received $457,107 across 1,850 general payments and $27,787 in research payments paid to them. Separately, studies naming them as principal investigator received $2,155,605 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,063 119
2024 General $47,118 185
2024 Research $1,801 12
2023 General $47,052 197
2023 Research $6,482 1
2022 General $73,571 301
2022 Research $19,504 2
2021 General $28,668 238
2020 General $65,389 300
2019 General $171,246 510

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Berner
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Jason Berner were reported at $24,063. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Jason Berner Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $171,246 $494 $123–$2,253 $163
2020 $65,389 $335 $85–$1,841 $114
2021 $28,668 $398 $88–$1,981 $132
2022 $73,571 $364 $88–$1,568 $149
2023 $47,052 $420 $113–$1,614 $160
2024 $47,118 $440 $121–$1,646 $164
2025 $24,063 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $291,789 620 payments
  2. Amarin Pharma Inc. $32,626 94 payments
  3. AstraZeneca Pharmaceuticals LP $29,356 86 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $27,140 114 payments
  5. Dexcom, Inc. $22,759 40 payments
  6. Abbott Laboratories $22,149 88 payments
  7. AbbVie, Inc. $6,914 30 payments
  8. Sanofi-Aventis U.S. LLC $4,719 85 payments
  9. Janssen Pharmaceuticals, Inc $2,569 10 payments
  10. Novo Nordisk Inc $2,125 187 payments
  11. Other $14,961 496 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $328,144 273 payments
  2. Travel and Lodging $51,973 228 payments
  3. Food and Beverage $30,201 1,296 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $30,049 21 payments
  5. Consulting Fee $12,180 11 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,600 5 payments
  7. Honoraria $600 1 payment
  8. Education $301 14 payments
  9. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. TRULICITY $116,885 250 payments
  2. MOUNJARO $101,886 167 payments
  3. JARDIANCE Diabetes $37,818 84 payments
  4. FARXIGA $28,984 82 payments
  5. Vascepa Hypertriglyceridemia $22,362 48 payments
  6. JARDIANCE Diabetes $22,358 92 payments
  7. DEXCOM G7 GSS (161) $22,316 21 payments
  8. DEXCOM STELO GLUCOSE BIOSENSOR $16,543 17 payments
  9. Vascepa Cardiovascular $10,265 46 payments
  10. FreeStyle Libre Pro $7,941 14 payments
  11. Other $53,678 1,093 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $26,678 4 payments
  2. AbbVie, Inc. $1,109 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

3,322

Median for Endocrinology: 1,959

Drug cost

$1,491,874

Median for Endocrinology: $890,201

Branded share of claims

61.2%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 257 $345,195
Mounjaro Tirzepatide Brand 217 $244,302
Jardiance Empagliflozin Brand 134 $132,291
Trulicity Dulaglutide Brand 98 $102,860
Farxiga Dapagliflozin Propanediol Brand 74 $83,750
Vascepa Icosapent Ethyl Brand 110 $79,355
Januvia Sitagliptin Phosphate Brand 50 $53,669
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 52 $50,387
Lyumjev Kwikpen U-100 Insulin Lispro-Aabc Brand 49 $42,649
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 31 $37,447

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$94,643

Medicare's payments for the services billed

Medicare patients

400

Average age 73

Services billed

2,217

235 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Arthritis 48%
Ischemic heart disease 42%
Chronic kidney disease 31%
Atrial fibrillation 18%
Depression 18%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$24,038 217 —
JARDIANCE
$10,688 134 —
TEPEZZA
$195 — —
TZIELD
$183 — —
RECORLEV
$146 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,865 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record